NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
- PMID: 11826411
- DOI: 10.1053/jhep.2002.30692
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
Abstract
Nonalcoholic steatohepatitis (NASH) is often linked with disorders that are clearly associated with insulin resistance (IR): obesity, type 2 diabetes mellitus, and hypertriglyceridemia. We tested the hypotheses that (1) IR is an essential requirement for the development of NASH and (2) a high association between IR and liver disease is relatively specific for NASH. We measured body mass index (BMI), waist/hip ratio, and fasting serum lipid, insulin, C-peptide, and glucose levels in 66 patients with NASH (21 with advanced fibrosis and 45 with mild fibrosis). IR was determined by the homeostasis model assessment (HOMA). We also determined the strength of the association of NASH with insulin resistance syndrome (IRS) as defined by World Health Organization criteria. To assess whether the finding of IR was relatively specific to NASH rather than simply to obesity or liver disease, we compared the results of a subset of 36 patients with less-severe NASH with 36 age- and sex-matched patients with chronic hepatitis C virus (HCV) of comparable fibrotic severity. IR was confirmed in 65 patients (98%) with NASH, and 55 (87%) fulfilled minimum criteria for IRS. IR was found in lean as well as in overweight and obese patients. The IR values and the prevalence of IRS (75% vs. 8.3%) were significantly higher in those with NASH than in comparable cases of HCV. Hyperinsulinemia was attributable to increased insulin secretion rather than decreased hepatic extraction. In conclusion, most patients with NASH have IRS, and there is a near-universal association between NASH and IR irrespective of obesity. IR is present in mild as well as advanced cases of NASH but is unusual in chronic HCV of similar fibrotic severity.
Comment in
-
NASH: from liver diseases to metabolic disorders and back to clinical hepatology.Hepatology. 2002 Feb;35(2):497-9. doi: 10.1053/jhep.2002.31551. Hepatology. 2002. PMID: 11826428 Review. No abstract available.
Similar articles
-
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.Hepatology. 2002 Feb;35(2):367-72. doi: 10.1053/jhep.2002.30690. Hepatology. 2002. PMID: 11826410
-
Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity.Obes Surg. 2008 Jul;18(7):847-53. doi: 10.1007/s11695-007-9355-0. Epub 2008 May 6. Obes Surg. 2008. PMID: 18459024
-
Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.J Clin Gastroenterol. 2014 Nov-Dec;48(10):883-8. doi: 10.1097/MCG.0000000000000065. J Clin Gastroenterol. 2014. PMID: 24440936
-
Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.Diabetes Metab. 2000 Apr;26(2):98-106. Diabetes Metab. 2000. PMID: 10804323 Review.
-
Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH.J Gastroenterol. 2005 Apr;40(4):329-36. doi: 10.1007/s00535-005-1586-z. J Gastroenterol. 2005. PMID: 15868369 Review.
Cited by
-
Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease.Indian J Clin Biochem. 2011 Apr;26(2):202-9. doi: 10.1007/s12291-011-0121-7. Epub 2011 Apr 7. Indian J Clin Biochem. 2011. PMID: 22468051 Free PMC article.
-
Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?J Obes. 2012;2012:483135. doi: 10.1155/2012/483135. Epub 2012 Dec 23. J Obes. 2012. PMID: 23320150 Free PMC article. Review.
-
Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.J Gastroenterol. 2014 Mar;49(3):481-91. doi: 10.1007/s00535-013-0783-4. Epub 2013 Mar 12. J Gastroenterol. 2014. PMID: 23475323
-
Role of receptor for advanced glycation end products (RAGE) in liver disease.Eur J Med Res. 2015 Feb 11;20(1):15. doi: 10.1186/s40001-015-0090-z. Eur J Med Res. 2015. PMID: 25888859 Free PMC article. Review.
-
Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians.World J Gastroenterol. 2006 Jun 7;12(21):3400-5. doi: 10.3748/wjg.v12.i21.3400. World J Gastroenterol. 2006. PMID: 16733858 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical